KYLYS Aesthetics was honored to be invited to present its technology at the inaugural Medical Aesthetic Injectable Summit 2024 (MAIS 2024), a leading international event dedicated to innovation and scientific advances in injectable aesthetic medicine.
The summit brought together key stakeholders from across the industry, including physicians, researchers, and companies shaping the future of medical aesthetics. As part of the Innovation Summit, KYLYS had the opportunity to showcase its proprietary hyaluronic acid–based technology and share its vision for the next generation of injectable treatments.
During the presentation, the KYLYS team introduced the scientific foundations of its platform, developed from research originating at the University of Geneva, and discussed how its formulation technology aims to improve tissue integration while opening new possibilities for regenerative aesthetics.
The event provided a valuable forum to exchange ideas with leading practitioners and industry experts, as well as to discuss emerging trends in injectable technologies, safety profiles, and regenerative approaches in aesthetic medicine.
Participation in MAIS 2024 reflects the growing interest from the medical aesthetics community in innovative solutions that go beyond traditional volumizing fillers and move toward safer, longer-lasting, and biologically active treatments.
KYLYS Aesthetics would like to thank the organizers of the Medical Aesthetic Injectable Summit for the invitation and the opportunity to present its work among such an inspiring group of experts and innovators.
As the field of aesthetic medicine continues to evolve, KYLYS remains committed to advancing technologies that combine scientific rigor, clinical validation, and meaningful innovation for patients and practitioners.